Gut microbiota and immunotherapy of renal cell carcinoma
File(s)
Author(s)
Type
Journal Article
Abstract
The gut microbiome has recently been proposed as a key player in cancer development and progression. Several studies have reported that the composition of the gut microbiome plays a role in the response to immune checkpoint inhibitors (ICIs). The gut microbiome modulation has been investigated as a potential therapeutic strategy for cancer, mainly in patients undergoing therapy with ICIs. In particular, modulation through probiotics, FMT or other microbiome-related approaches have proven effective to improve the response to ICIs. In this review, we examine the role of the gut microbiome in enhancing clinical responses to ICIs in the treatment of renal cancer.
Date Issued
2023
Date Acceptance
2023-10-06
Citation
Human Vaccines and Immunotherapeutics, 2023, 19 (3)
ISSN
2164-554X
Publisher
Taylor and Francis Group
Journal / Book Title
Human Vaccines and Immunotherapeutics
Volume
19
Issue
3
Copyright Statement
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
License URL
Identifier
https://www.tandfonline.com/doi/full/10.1080/21645515.2023.2268982
Publication Status
Published
Article Number
2268982
Date Publish Online
2023-11-13